Key terms
About IOBT
IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest IOBT news
Apr 15
8:42am ET
IO Biotech appoints Shamsaei as SVP, Commercial Development
Apr 05
8:33am ET
IO Biotech appoints Faical Miyara as CBO
Mar 06
7:40am ET
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alnylam Pharma (ALNY) and IO Biotech (IOBT)
Mar 06
6:38am ET
Buy Recommendation for IO Biotech on Strong Data Prospects and Undervalued Stock Position
Mar 05
4:44pm ET
IO Biotech reports Q4 EPS (40c), consensus (39c)
No recent press releases are available for IOBT
IOBT Financials
Key terms
Ad Feedback
IOBT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IOBT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
